Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age

Chronic blood transfusions start at a very young age in subjects with transfusion‐dependent anemias, the majority of whom have hereditary anemias. To understand how rapidly iron overload develops, we retrospectively reviewed 308 MRIs for evaluation of liver, pancreatic, or cardiac iron in 125 subjec...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 88; no. 11; pp. E283 - E285
Main Authors Berdoukas, Vasilios, Nord, Anne, Carson, Susan, Puliyel, Mammen, Hofstra, Thomas, Wood, John, Coates, Thomas D.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.11.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chronic blood transfusions start at a very young age in subjects with transfusion‐dependent anemias, the majority of whom have hereditary anemias. To understand how rapidly iron overload develops, we retrospectively reviewed 308 MRIs for evaluation of liver, pancreatic, or cardiac iron in 125 subjects less than 10 years old. Median age at first MRI evaluation was 6.0 years. Median liver iron concentrations in patients less than 3.5 years old were 14 and 13 mg/g dry weight in thalassemia major (TM) and Diamond–Blackfan anemia (DBA) patients, respectively. At time of first MRI, pancreatic iron was markedly elevated (> 100 Hz) in DBA patients, and cardiac iron ( R2* >50 Hz) was present in 5/112 subjects (4.5%), including a 2.5 years old subject with DBA. Five of 14 patients (38%) with congenital dyserythropoietic anemia (CDA) developed excess cardiac iron before their 10th birthday. Thus, clinically significant hepatic and cardiac iron accumulation occurs at an early age in patients on chronic transfusions, particularly in those with ineffective or absent erythropoiesis, such as DBA, CDA, and TM, who are at higher risk for iron cardiomyopathy. Performing MRI for iron evaluation in the liver, heart, and pancreas as early as feasible, particularly in those conditions in which there is suppressed bone marrow activity is very important in the management of iron loaded children in order to prescribe appropriate chelation to prevent long‐term sequelae. Am. J. Heamtol. 88:E283–E285, 2013. © 2013 Wiley Periodicals, Inc.
Bibliography:Conflict of interest: VB is a consultant for Apo Pharma. TDC is a consultant/speaker for Apo Pharma, Novartis, and Shire Pharma. JW is a consultant for Shire Pharma, Novartis Pharma, and Apo Pharma. VB, JW, and TC have received no compensation from any of these entities related to any aspect of this work. SC is on the speaker's bureau for Novartis Pharma. None of these individuals have received any compensation from these entities related to this work. AN, MP, TH have no conflicts to report
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.23543